JP2014534196A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534196A5
JP2014534196A5 JP2014535789A JP2014535789A JP2014534196A5 JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5 JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014534196 A5 JP2014534196 A5 JP 2014534196A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rasagiline
weight
amount
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059356 external-priority patent/WO2013055687A2/en
Publication of JP2014534196A publication Critical patent/JP2014534196A/ja
Publication of JP2014534196A5 publication Critical patent/JP2014534196A5/ja
Pending legal-status Critical Current

Links

JP2014535789A 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン Pending JP2014534196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (2)

Publication Number Publication Date
JP2014534196A JP2014534196A (ja) 2014-12-18
JP2014534196A5 true JP2014534196A5 (cg-RX-API-DMAC10.html) 2015-12-03

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535789A Pending JP2014534196A (ja) 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Country Status (15)

Country Link
US (1) US9346746B2 (cg-RX-API-DMAC10.html)
EP (1) EP2766002A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014534196A (cg-RX-API-DMAC10.html)
KR (1) KR20140090996A (cg-RX-API-DMAC10.html)
CN (1) CN103874487A (cg-RX-API-DMAC10.html)
AR (1) AR088297A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012323349A1 (cg-RX-API-DMAC10.html)
BR (1) BR112014008555A2 (cg-RX-API-DMAC10.html)
CA (1) CA2851276A1 (cg-RX-API-DMAC10.html)
EA (1) EA201490761A1 (cg-RX-API-DMAC10.html)
HK (1) HK1200315A1 (cg-RX-API-DMAC10.html)
IL (1) IL231721A0 (cg-RX-API-DMAC10.html)
MX (1) MX2014004308A (cg-RX-API-DMAC10.html)
WO (1) WO2013055687A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201403043B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5914349A (en) * 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
EP0738149B1 (en) * 1994-01-10 2006-11-29 Teva Pharmaceutical Industries, Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
JP2003512426A (ja) * 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
WO2004072250A2 (en) 2003-02-06 2004-08-26 University Of Georgia Research Foundation, Inc. Galacturonosyl transferases, nucleic acids encoding same and uses therefor
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
UA97382C2 (ru) 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2296462A4 (en) 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
JP2011525489A (ja) 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
JP2013507352A (ja) 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011087791A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
CN103188933A (zh) 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
US20130089611A1 (en) 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina

Similar Documents

Publication Publication Date Title
JP2014534197A5 (cg-RX-API-DMAC10.html)
TW201605446A (zh) 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之修飾釋放調配物
JP2012512907A5 (cg-RX-API-DMAC10.html)
CN104334169B (zh) 包含氨基羧酸盐的固体组合物
CN102114011B (zh) 一种布洛芬缓释制剂及其制备方法
CN101322695B (zh) 双氯芬酸钾缓释胶囊及其生产工艺
CN103585122B (zh) 一种含依维莫司的片剂及其制备方法
CN103830192A (zh) 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法
KR20150092385A (ko) 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
CN106943367B (zh) 一种马来酸阿法替尼片及其制备方法
WO2018230504A1 (ja) 顆粒剤、並びに錠剤及びその製造方法
CN103142540B (zh) 一种甘糖酯控释片及其制备方法
CN104706606B (zh) 一种枸橼酸西地那非片剂及其制备方法
CN106478598B (zh) 一种凡德他尼水合物晶体及其制备方法
CN103768034A (zh) 一种含有盐酸安非他酮的缓控释固体组合物
CN103142533B (zh) 一种依托泊苷肠溶片
CN106943368A (zh) 米氮平片剂及其制备方法
CN101032484A (zh) 一种噻托溴铵胶囊型吸入粉雾剂
JPWO2017064814A1 (ja) ジエノゲスト含有錠剤
EP2531180A2 (en) Oral complex composition comprising pseudoephedrine and levocetirizine
CN103735520B (zh) 一种间苯三酚颗粒剂及其制备方法
CN110038013A (zh) 一种头孢呋辛酯固体制剂及其制备工艺
Chaturvedi et al. Comparative Evaluation Of Natural And Semisynthetic Superdisintegrants In The Formulation Of Orodispersible Tablets of Norfloxacin
CN105769807B (zh) 一种含有非诺贝酸胆碱的药物组合物
CN103142530B (zh) 一种依托泊苷缓释片